Kodiak Sciences (KOD) Common Equity (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Common Equity came in at $112.1 million in Q1 2026, up 2.99% YoY from $108.8 million in Q1 2025, and down 28.77% on a QoQ basis from $157.4 million in Q4 2025.
Kodiak Sciences (KOD) Common Equity (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Common Equity data on file, last reported at $112.1 million in Q1 2026.
- Quarterly Common Equity rose 2.99% year-over-year to $112.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.1 million (up 2.99% YoY) and the FY2025 annual result came in at $157.4 million, up 4.72% from the prior year.
- Common Equity slipped to $112.1 million in Q1 2026, from $157.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $597.4 million in Q1 2022 to a low of $23.7 million in Q3 2025.
- A 5-year average of $271.0 million and a median of $241.2 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 4.72% in 2025, down 87.22% in 2025.
- Tracing KOD's Common Equity over 5 years: stood at $436.2 million in 2022, then tumbled by 39.06% to $265.8 million in 2023, then sank by 43.45% to $150.3 million in 2024, then increased by 4.72% to $157.4 million in 2025, then dropped by 28.77% to $112.1 million in 2026.
- The last three Common Equity figures came in at $112.1 million (Q1 2026), $157.4 million (Q4 2025), and $23.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | 61.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.10 Mn |
| Mar 31, 2026 | 112.10 Mn |
| Dec 31, 2025 | 157.38 Mn |
| Sep 30, 2025 | 23.69 Mn |
| Jun 30, 2025 | 70.29 Mn |
| Mar 31, 2025 | 108.84 Mn |
| Dec 31, 2024 | 150.29 Mn |
| Sep 30, 2024 | 185.37 Mn |
| Jun 30, 2024 | 214.51 Mn |
| Mar 31, 2024 | 241.19 Mn |
| Dec 31, 2023 | 265.78 Mn |
| Sep 30, 2023 | 302.42 Mn |
| Jun 30, 2023 | 338.48 Mn |
| Mar 31, 2023 | 392.59 Mn |
| Dec 31, 2022 | 436.17 Mn |
| Sep 30, 2022 | 479.53 Mn |
| Jun 30, 2022 | 530.93 Mn |
| Mar 31, 2022 | 597.38 Mn |
| Dec 31, 2021 | 663.32 Mn |
| Sep 30, 2021 | 726.32 Mn |